Work

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Year: 2015

Type: conference-abstract

Abstract: Meeting abstracts HD IL-2 was FDA approved for advanced mRCC, but the data supporting its use dates to the 1990's. We designed the PROCLAIMSM registry, including retrospective and prospective cohorts, to study modern outcomes and interactions with prior or subsequent targeted therapies. We now

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p225

Authors: Joseph I Clark, Michael A Morse, Michael KK Wong, David F McDermott, Howard L Kaufman, Gregory A Daniels, Jessica C Perritt, Hong Hua, Sandra Aung

Institutions: Loyola University Medical Center, Loyola Medicine, Duke Medical Center, University of Southern California, Beth Israel Deaconess Medical Center, Rutgers Cancer Institute, University of California San Diego, Moores Cancer Center, Prometheus (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490

OpenAlex ID: W1945890823

Cites:

Cited by:

Related to: 10